Clinical Trial Update: Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating IMC-R117C in selected advanced cancers expressing HLA-A*02:01 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• IMC-R117C

Snippet

Sponsor: Immunocore Ltd | Conditions: Cancer, HLA-A*02:01-positive | Phase 1, Phase 2 | Status: RECRUITING